Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy may help liver cancer patients bridge to transplant

NCT ID NCT01918683

Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot trial is testing whether adding stereotactic body radiation therapy (SBRT) to the standard transarterial chemoembolization (TACE) can better control liver cancer in patients waiting for a liver transplant. About 40 patients will be enrolled to see if the combination improves progression-free survival until transplant. The goal is to keep the cancer from growing so patients can successfully receive a new liver.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transarterial chemoembolization (TACE) and stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this combination could help more liver cancer patients stay healthy enough to receive a transplant and improve their chances of a good outcome after surgery.
What could go wrong
This is a small, early pilot study with only 40 participants, so results may not apply to everyone. The combination of treatments may also cause side effects like liver damage or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Jul 2013

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient capable of giving informed consent * Patient diagnosed with hepatocellular carcinoma and listed or recommended to be listed for orthotopic liver transplantation at the participating institution * Age \> 18 years old * Meets clinical criteria for eligibility for TACE to the target lesion per Interventional Radiology * Childs' Class A or B7 * Eastern Clinical Oncology Group performance status 0 or 1 Exclusion Criteria: * Prior radiotherapy to the upper abdomen or radioembolization of the liver * Prior TACE to the target lesion, RFA, or liver transplant * Active GI bleed within 2 weeks of study enrollment * Active GI ulcer disease within 4 weeks of study enrollment * Ascites refractory to medical therapy * Contraindication to receiving radiotherapy or TACE * Complete obstruction of portal venous flow to the segment of liver that includes the target lesion * Contraindication to both contrast enhanced MRI and contrast enhanced CT (i.e. unable to undergo follow-up imaging or SBRT treatment planning) * Women who are pregnant * Participation in another concurrent treatment protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Loyola University Medical Center

    Maywood, Illinois, 60153, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.